Annexon Inc Asset Resilience Ratio
Annexon Inc asset resilience ratio. Annexon Inc (ANNX) has an Asset Resilience Ratio of 4.05% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Annexon Inc (ANNX) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Annexon Inc (2020–2025)
Asset resilience ratio of Annexon Inc from 2020 to 2025. This chart shows how Annexon Inc's Asset Resilience Ratio has changed over time. Read ANNX total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Annexon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ANNX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.97 Million | 4.05% |
| Total Liquid Assets | $9.97 Million | 4.05% |
Asset Resilience Insights
- Limited Liquidity: Annexon Inc maintains only 4.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Annexon Inc Industry Peers by Asset Resilience Ratio
Compare Annexon Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Annexon Inc Asset Resilience Ratio by Year (2020–2025)
Annexon Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Annexon Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.49% | $76.29 Million | $277.57 Million | -47.50pp |
| 2024-12-31 | 74.99% | $262.52 Million | $350.07 Million | +63.36pp |
| 2023-12-31 | 11.63% | $34.61 Million | $297.67 Million | -24.38pp |
| 2022-12-31 | 36.00% | $102.64 Million | $285.10 Million | -22.48pp |
| 2021-12-31 | 58.48% | $167.87 Million | $287.04 Million | +35.27pp |
| 2020-12-31 | 23.22% | $82.64 Million | $355.95 Million | -- |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase… Read more